OTCMKTS:SPHRY Starpharma (SPHRY) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free SPHRY Stock Alerts $0.66 -0.09 (-12.05%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$0.66▼$0.7050-Day Range$0.66▼$0.9252-Week Range$0.66▼$2.81Volume7,225 shsAverage Volume334 shsMarket Capitalization$27.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Starpharma alerts: Email Address Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Starpharma Stock (OTCMKTS:SPHRY)Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.Read More SPHRY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPHRY Stock News HeadlinesMarch 14, 2024 | wsj.comStarpharma Holdings Ltd. ADRFebruary 19, 2024 | markets.businessinsider.comStarpharma's VivaGel Approval Denied By FDAFebruary 18, 2024 | msn.comASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pcJanuary 19, 2024 | morningstar.comStarpharma Holdings Ltd SPLJanuary 6, 2024 | afr.comStarpharma Holdings LimitedNovember 29, 2023 | finance.yahoo.comStarpharma Holdings Limited (SPHRY)November 8, 2023 | investing.comStarpharma Holdings (SPHRY) Earnings Dates & ReportsJuly 27, 2023 | seekingalpha.comStarpharma: Patience Needed, But A Lot To LikeJune 9, 2023 | msn.comThe Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreakOctober 24, 2022 | finance.yahoo.comVIRALEZE Nasal Spray to be distributed in Hong Kong and MacauSeptember 12, 2022 | finance.yahoo.comStarpharma presents compelling data in Prostate Cancer at ESMOAugust 10, 2022 | finance.yahoo.comStarpharma signs new DEP® agreement with MSDJuly 20, 2022 | finanznachrichten.deStarpharma: VIRALEZE Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral ExposureJanuary 12, 2022 | nasdaq.comStarpharma Holdings Ltd. ADR (SPHRY)December 13, 2021 | msn.comWhat is happening to the Starpharma (ASX:SPL) share price today?December 6, 2021 | msn.comStarpharma (ASX:SPL) share price shoots 6% higher on Roche agreementNovember 19, 2021 | msn.comWhy is the Starpharma (ASX:SPL) share price trading at 52-week lows?October 28, 2021 | markets.businessinsider.comPerth businesswoman Kim Tran launches new business, scores supply deal with StarpharmaOctober 26, 2021 | msn.comStarpharma (ASX:SPL) share price lifts on supply and distribution dealOctober 8, 2021 | finance.yahoo.comVIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in ItalySeptember 15, 2021 | apnews.comUS Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma’s phase 2 clinical-stage cancer treatmentsSeptember 15, 2021 | finance.yahoo.comUS Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatmentsAugust 26, 2021 | msn.comStarpharma (ASX:SPL) share price tanks 3% on 67% revenue dropJuly 26, 2021 | msn.comWhy the Starpharma (ASX:SPL) share price is racing 7% higher todaySee More Headlines Receive SPHRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/30/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolOTCMKTS:SPHRY CUSIPN/A CIKN/A Webwww.starpharma.com Phone(138) 532-2700Fax61-3-9510-5955Employees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.83 million Price / Sales9.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.15Miscellaneous Outstanding Shares41,200,000Free FloatN/AMarket Cap$27.06 million OptionableNot Optionable Beta1.07 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Justin CahillCFO & Company SecretaryMs. Cheryl Maley B.Sc. (Age 55)M.B.A., CEO, MD & Director Key CompetitorsLuna InnovationsNASDAQ:LUNAOneMedNetNASDAQ:ONMDInotivNASDAQ:NOTVAuxly Cannabis GroupOTCMKTS:CBWTFHedgePath PharmaceuticalsOTCMKTS:HPPIView All Competitors SPHRY Stock Analysis - Frequently Asked Questions How have SPHRY shares performed in 2024? Starpharma's stock was trading at $1.2440 at the beginning of 2024. Since then, SPHRY stock has decreased by 47.2% and is now trading at $0.6568. View the best growth stocks for 2024 here. Are investors shorting Starpharma? Starpharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,800 shares, an increase of 21.7% from the April 30th total of 2,300 shares. Based on an average daily volume of 700 shares, the short-interest ratio is currently 4.0 days. View Starpharma's Short Interest. How do I buy shares of Starpharma? Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SPHRY) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Starpharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.